Document:

exv4wc

 

Exhibit 4(c)

AMENDMENT NO. 1 TO RIGHTS AGREEMENT

     This Amendment No. 1 to Rights Agreement (this “Amendment”), dated as of April 22,
2008, is made between Synaptics Incorporated, a Delaware corporation (the “Company”), and
American Stock Transfer & Trust Company, as rights agent (the “Rights Agent”), at the
direction of the Company.

Recitals

     WHEREAS, the Company and the Rights Agent are parties to that certain Rights Agreement, dated
as of August 15, 2002 (the “Agreement”);

     WHEREAS, the Company, pursuant to Section 27 of the Agreement, desires to amend the
Agreement;

     WHEREAS, this Amendment does not change the Redemption Price; and

     WHEREAS, pursuant to Section 27 of the Agreement, the Company has delivered a certificate from
an appropriate officer of the Company which states that this Amendment is in compliance with the
terms of Section 27 of the Agreement and the Company has further directed the Rights Agent to join
in this Amendment.

     NOW, THEREFORE, for and in consideration of the premises and the mutual agreements set forth
in this Amendment, and for other good and valuable consideration the receipt and sufficiency of
which is hereby acknowledged, the Agreement is hereby amended as follows:

Agreement

     1. Amendment to Section 1(a). The text of subsection (a) of Section 1 of the Rights
Agreement is deleted in its entirety, and the following is inserted in lieu thereof:

“(a) “Acquiring Person” shall mean any Person (as such term is
hereinafter defined) who or which shall be the Beneficial Owner (as
such term is hereinafter defined) of 15% or more of the shares of
Common Stock then outstanding, but shall not include (i) an Exempt
Person (as such term is hereinafter defined) or (ii) any Person who or
which shall be the Beneficial Owner of 15% or more of the shares of
Common Stock then outstanding by virtue of a purchase or purchases
made on a national securities exchange in reliance upon information
set forth in a quarterly or an annual report filed by the Company with
the Securities and Exchange Commission unless and until such time as
such Person shall, after such purchase or purchases, become the
Beneficial Owner of additional shares of Common Stock (other than
pursuant to a dividend or distribution paid or made by the Company on
the outstanding Common Stock or pursuant to a split or subdivision of
the outstanding Common Stock), unless upon becoming the Beneficial
Owner of such additional shares of Common Stock, such Person is not
then the Beneficial Owner of 15% or more

 

 

of the shares of Common Stock then outstanding; provided, however,
that (i) if the Board of Directors of the Company determines in good
faith that a Person who would otherwise be an “Acquiring Person”
became the Beneficial Owner of a number of shares of Common Stock such
that the Person would otherwise qualify as an “Acquiring Person”
inadvertently (including, without limitation, because (A) such Person
was unaware that it beneficially owned a percentage of Common Stock
that would otherwise cause such Person to be an “Acquiring Person” or
(B) such Person was aware of the extent of its Beneficial Ownership of
Common Stock but had no actual knowledge of the consequences of such
Beneficial Ownership under this Agreement) and without any intention
of changing or influencing control of the Company, then such Person
shall not be deemed to be or to have become an “Acquiring Person” for
any purposes of this Agreement unless and until such Person shall have
failed to divest itself, as soon as practicable (as determined, in
good faith, by the Board of Directors of the Company), of Beneficial
Ownership of a sufficient number of shares of Common Stock so that
such Person would no longer otherwise qualify as an “Acquiring
Person”, (ii) if, as of the date of this Agreement or prior to the
first public announcement of the adoption of this Agreement, any
Person is or becomes the Beneficial Owner of 15% or more of the shares
of Common Stock outstanding, such Person shall not be deemed to be or
to become an “Acquiring Person” unless and until such time as such
Person shall, after the first public announcement of the adoption of
this Agreement, become the Beneficial Owner of additional shares of
Common Stock (other than pursuant to a dividend or distribution paid
or made by the Company on the outstanding Common Stock or pursuant to
a split or subdivision of the outstanding Common Stock), unless, upon
becoming the Beneficial Owner of such additional shares of Common
Stock, such Person is not then the Beneficial Owner of 15% or more of
the shares of Common Stock then outstanding, and (iii) no Person shall
become an “Acquiring Person” as the result of an acquisition of shares
of Common Stock by the Company which, by reducing the number of shares
outstanding, increases the proportionate number of shares of Common
Stock beneficially owned by such Person to 15% or more of the shares
of Common Stock then outstanding, provided, however, that if a Person
shall become the Beneficial Owner of 15% or more of the shares of
Common Stock then outstanding by reason of such share acquisitions by
the Company and shall thereafter become the Beneficial Owner of any
additional shares of Common Stock (other than pursuant to a dividend
or distribution paid or made by the Company on the outstanding Common
Stock or pursuant to a split or subdivision of the outstanding Common
Stock), then such Person shall be deemed to be an “Acquiring Person”
unless upon becoming the Beneficial Owner of such additional shares of
Common Stock

2

 

such Person does not beneficially own 15% or more of the shares of
Common Stock then outstanding. For all purposes of this Agreement, any
calculation of the number of shares of Common Stock outstanding at any
particular time, including for purposes of determining the particular
percentage of such outstanding shares of Common Stock of which any
Person is the Beneficial Owner, shall be made in accordance with the
last sentence of Rule 13d-3(d)(1)(i) of the General Rules and
Regulations under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), as in effect on the date hereof.”

     2. Effectiveness. This Amendment shall, pursuant to Section 27 of the Agreement,
become effective immediately upon execution of this Amendment by the Company on the date first
above written, whether or not also executed by the Rights Agent.

     3. Effectiveness of Agreement. Except as expressly amended by this Amendment, the
Agreement shall remain in full force and effect, and all references to the Agreement from and after
such time shall be deemed to be references to the Agreement as amended hereby.

     4. Severability. The parties intend that this Amendment be enforced and interpreted
as written. If, however, any term, provision, covenant, or restriction of this Amendment is held
by a court of competent jurisdiction or other authority to be invalid, void, or unenforceable, the
remainder of the terms, provisions, covenants, and restrictions of this Amendment shall remain in
full force and effect and shall in no way be affected, impaired, or invalidated.

     5. Governing Law. This Amendment shall be deemed to be a contract made under the laws
of the state of Delaware and for all purposes shall be governed by and construed in accordance with
the laws of such state applicable to contracts to be made and performed entirely within such state.

     6. Counterparts. This Amendment may be executed in any number of counterparts and
each of such counterparts shall for all purposes be deemed to be an original, and all such
counterparts shall together constitute but one and the same instrument.

     7. Descriptive Headings. Descriptive headings of the several sections, subsections,
and provisions of this Amendment are inserted for convenience of reference only and shall not
control or affect the meaning, interpretation, or construction of any of the terms or provisions
hereof.

     8. Capitalized Terms. Capitalized terms used in this Amendment and not otherwise
defined herein shall have the meaning ascribed to such terms in the Agreement.

[Remainder of Page Intentionally Left Blank]

3

 

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of
the day and year first above written.

	 	 	 	 	 	 	 
	 	 	SYNAPTICS INCORPORATED	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	/s/ Francis F. Lee
 

	 	 
	 

	 	Name:
	 	Francis F. Lee	 	 
	 

	 	Title:
	 	President & Chief Executive Officer	 	 
	 
	 	 	 	 	 	 
	 	 	AMERICAN STOCK TRANSFER & TRUST COMPANY	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	/s/ Herbert J. Lemmer
 

	 	 
	 

	 	Name:
	 	Herbert J. Lemmer	 	 
	 

	 	Title:
	 	Vice President	 	 

4ex101.htm

    EXHIBIT
10.1

     

    MONTGOMERY
EQUITY PARTNERS, LTD.

    101
Hudson Street

    Suite
3700

    Jersey
City, New Jersey 07092

    

    

    April 22,
2008

    

    

    Medical
Diagnostic Innovations Ltd.

    3rd Floor,
14 South Molton Street,

    London W1K 5QP, United
Kingdom

    ATTN:  Mr.
Graham Cooper

    

    In
Veritas Medical Diagnostics, Inc.

    The Green
House

    Beechwood
Business Park North

    Inverness
– Scotland L2 IV2 3BL

    ATTN:

    

    Re:           Proposed  Assignment of
Debenture No. MEP-1, dated September 7, 2005 in the original principal amount of
$300,000 (the “Debenture”) issued by In Veritas Medical Diagnostics, Inc. (“In
Veritas,” or the “Company”) to Montgomery Equity Partners, Ltd.
(“Montgomery”)

    

    Dear Mr.
Cooper:

    

    We
understand that Medical Diagnostic Innovations Ltd. (“MDI”) is interested in
purchasing the Debenture from Montgomery and understand further that you intend
to enter into a subscription agreement (the “Subscription Agreement”), pursuant
to which you will purchase common shares of In Veritas for $0.05 per
share.

    

    

    We will
agree to assign the Debenture, and all related Transaction Documents (as that
term is defined in the Debenture, and other than any warrants) , and release any
shares of the Company held in escrow by Montgomery pursuant to the Escrow
Agreement between the Company and Montgomery dated September 7, 2005), on a non-recourse
basis, on the following terms and conditions:

    

    
      	
              1.  

            	
              Within
      five (5) days of the date hereof, MDI shall pay Montgomery Fifty Thousand
      Dollars ($50,000) by wire transfer in immediately available
      funds.  This amount shall be retained by Montgomery (to be
      applied to interest, fees, or principal due under the Debenture, at its
      sole discretion) whether or not each of the transactions contemplated by
      this agreement are finalized.

            

    

    

    
      	
              2.  

            	
              Within
      sixty (60) days of the date hereof, MDI shall pay Montgomery Two Hundred
      Thousand Dollars ($200,000) by wire transfer in immediately available
      funds.  (The date on which such payment is received by
      Montgomery shall be deemed the “Final Payment
  Date”)

            

    

    

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

     

    If each
of the above conditions is satisfied:

    

    
      	
              3.  

            	
              Within
      three (3) days of the Final Payment Date, Montgomery will assign a
      principal balance of $250,000 of the Debenture and applicable Transaction
      Documents to MDI on a non-recourse basis, by executing an agreement
      substantially in the form attached hereto as Exhibit
  A.

            

    

    

    
      	
              4.  

            	
              Within
      three (3) days of the Final Payment Date, Montgomery will effectuate a
      conversion of the entire remaining balance owed on the Debenture into
      shares of In Veritas at a price per share equal to the lower
      of:  (a) Five Cents; and (b) the net purchase price per share
      provided for in the Subscription Agreement.  The conversion
      shall be effectuated pursuant to the terms of the Debenture, other than
      the amendment of the conversion price set forth in this Letter
      Agreement.  The Company agrees that it will fully honor a
      conversion notice with the conversion price set forth herein, and deliver
      all shares set forth in the notice to Montgomery, in accordance with the
      terms of the Debenture.  Failure of the Company to honor the
      conversion notice in accordance with the terms of this Letter Agreement
      shall fully vitiate Montgomery’s obligations
  hereunder.

            

    

    

    
      	
              5.  

            	
              Simultaneously
      with the final execution of the assignment agreement set forth in
      paragraph 3, the Company shall issue a warrant to Montgomery to purchase
      Five Million (5,000,000) shares of common stock of the Company at an
      exercise price of $0.05 per share, in the form attached hereto as Exhibit
      B.  Failure of the Company to issue such a warrant shall fully
      vitiate Montgomery’s obligations
hereunder.

            

    

    

    
      	
              6.  

            	
              No
      party may assign any of its rights hereunder without the prior consent of
      the other party hereto; provided that MDI may, without the consent of any
      other party, assign all or any portion of its rights hereunder to any
      of its Affiliates. Subject to the preceding sentence, this Agreement will
      apply to, be binding in all respects upon, and inure to the benefit of the
      successors and permitted assigns of the parties.  Nothing
      expressed or referred to in this Agreement will be construed to give any
      Person other than the parties to this Agreement any legal or equitable
      right, remedy, or claim under or with respect to this Agreement or any
      provision of this Agreement.  This Agreement and all of its
      provisions and conditions are for the sole and exclusive benefit of the
      parties to this Agreement and their successors and
  assigns.

            

    

    

    

    If these
terms are acceptable to you, please indicate your acceptance by signing in the
space provided below.

    

    [END
OF PAGE; SIGNATURE PAGE TO FOLLOW]

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    
       

    

    
      	 	MEDICAL
      DIAGNOSTICS, INC.	 
	 	 	 	 
	 	
              By:
      

            	/s/ Graham
      Cooper	 
	 	 	      
              Name:
      Graham Cooper

            	 
	 	 	      
              Title:
      Director

            	 
	 	 	 	 

    

     

    
      
        	 	IN VERITAS
      MEDICAL DIAGNOSTICS, INC.	 
	 	 	 	 
	 	
                By:
      

              	/s/ Martin
      Thorp      	 
	 	 	      
                Name:
      Martin Thorp

              	 
	 	 	      
                Title:
      Chief Financial Officer

              	 
	 	 	 	 

      

    

     

    
      
        	 	
                MONTGOMERY EQUITY PARTNERS,
      LTD.

                By Yorkville Advisors LLC

                Its Investment Manager

              	 
	 	 	 	 
	 	
                By:
      

              	/s/ David
      Gonzalez        	 
	 	 	      
                Name:
      David Gonzalez

              	 
	 	 	
                Title Member

              	 
	 	 	 	 

      

    3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]